Skip to main content
padlock icon - secure page this page is secure

Serum levels of antispermassociated antigen 9 antibody are elevated in patients with hepatocellular carcinoma

Buy Article:

$42.00 + tax (Refund Policy)

At present, there is a high incidence of viral hepatitis and high mortality rates due to hepatocellular carcinoma (HCC) in China. In the current study, the quantification of antibodies against the cancertestis antigen spermassociated antigen 9 (SPAG9), alone and combined with αfetoprotein (AFP), were evaluated as biomarkers for the diagnosis of HCC. The levels of antiSPAG9 antibody and AFP were quantified in serum samples from patients with HCC and hepatitis or cirrhosis, as well as healthy volunteers. The results revealed that the serum levels of antiSPAG9 immunoglobulin G antibody in patients with HCC were significantly higher compared with those in patients with hepatitis/cirrhosis and healthy controls. Using receiver operator characteristic curves, the area under the curve (AUC, 0.870) of SPAG9 as a diagnostic marker of HCC was significant [P<0.001; 95% confidence interval (CI), 0.7930.947], whereas the AUC of AFP was 0.832 (P<0.001; 95% CI, 0.7360.928). Serum antiSPAG9 antibody levels exhibited significant potential for the differential diagnosis of HCC, with an AUC value of 0.729, (P=0.008; 95% CI, 0.5590.899). Similarly, serum AFP levels exhibited significant value for the differential diagnosis of HCC, with an AUC value of 0.842 (P<0.001; 95% CI, 0.7320.953). When combined with quantification of AFP, the diagnostic sensitivity and specificity of antiSPAG9 levels were increased. In summary, the results suggested that antiSPAG9 antibody is a potential early diagnostic marker of HCC.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Affiliations: 1: Clinical Laboratory, Hunan Provincial Second People's Hospital, Changsha Hunan 410007, P.R. China 2: Clinical Medical School, Hunan University of Chinese Medicine, Changsha, Hunan 410007, P.R. China 3: Department of Immunology, School of Basic Medicine, Central South University, Changsha, Hunan 410078, P.R. China

Publication date: January 1, 2017

More about this publication?
  • Oncology Letters is a monthly, peer-reviewed journal, available in print and online, that focuses on all aspects of clinical oncology, as well as in vitro and in vivo experimental model systems relevant to the mechanisms of disease.

    The principal aim of Oncology Letters is to provide the prompt publication of original studies of high quality that pertain to clinical oncology, chemotherapy, oncogenes, carcinogenesis, metastasis, epidemiology and viral oncology in the form of original research, reviews and case reports.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more